Aim Immunotech - AIM STOCK NEWS

AIM ImmunoTech Inc. (NYSE: AIM) announced that CEO Thomas K. Equels will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL, and virtually. The company focuses on developing therapeutics for cancer, immune disorders, and viral diseases, including COVID-19. A video webcast of the presentation will be available on-demand starting May 24, 2022. AIM's lead product, Ampligen®, is in clinical trials for various cancers and is approved for treatment of ME/CFS in Argentina.

AIM ImmunoTech Inc. (NYSE: AIM) announced progress in its research on Ampligen, aimed at treating Long COVID and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). A Phase 3 trial indicated a 51.2% positive response in patients with early ME/CFS symptoms. Following promising results from an expanded access program, AIM plans to file an Investigational New Drug application for a Phase 2 study of Ampligen. Experts express optimism about Ampligen's potential benefits for Long COVID patients, highlighting the urgency for effective therapeutics.

AIM ImmunoTech Inc. (NYSE: AIM) reported significant clinical advancements in the first quarter of 2022, showcasing Ampligen's efficacy in late-stage pancreatic cancer, ovarian cancer, and triple-negative breast cancer. The company is on track to begin a Phase 2 study for Ampligen in pancreatic cancer by Q3 2022. AIM also holds a robust cash position of $44.5 million, expected to support operations through 2023. The FDA has lifted the clinical hold on its IND application, allowing further studies to proceed.

AIM ImmunoTech Inc. (NYSE: AIM) announced participation in the Solve M.E. Diagnostics event on May 19, 2022, focusing on Long COVID and its implications. CEO Thomas K. Equels will discuss the clinical development of Ampligen for treating ME/CFS and Long COVID. Ampligen, AIM's RNA product candidate, is designed to modulate the immune system and has shown anti-viral properties. The company sponsors an expanded access program for ME/CFS patients in the U.S., having dosed its first Long Hauler patient in this initiative in 2021.

AIM ImmunoTech Inc. (AIM) reported promising results from clinical studies involving Ampligen, an anti-tumor drug with potential synergy when combined with PD-1 and PD-L1 checkpoint inhibitors. Ampligen shows efficacy in treating triple-negative breast cancer and advanced recurrent ovarian cancer, as evidenced by significant survival rates in pre-clinical and human studies. The company aims to expand Ampligen's application to solid tumors based on emerging clinical data. Key findings include increased immune response markers and indications of tumor microenvironment reprogramming that could enhance treatment outcomes.

AIM ImmunoTech Inc. announced promising results for Ampligen® (rintatolimod) as a potential maintenance therapy for advanced pancreatic cancer. Following FDA clearance, AIM will commence a Phase 2 study (AMP-270) in Q3 2022, comparing Ampligen to a no-treatment control after FOLFIRINOX chemotherapy. The trial will enroll around 90 patients at multiple sites in the U.S. and Europe. Recent data showed improved median survival times for patients treated with Ampligen compared to historical controls, indicating its potential effectiveness in this challenging indication.

AIM ImmunoTech announced positive results from a Phase 1 study on metastatic triple-negative breast cancer (mTNBC), utilizing chemokine modulation therapy with Ampligen and pembrolizumab. The trial met its primary endpoint by enhancing cytotoxic T-lymphocyte infiltration in the tumor microenvironment. Results indicated significant disease stabilization in three out of six patients and impressive immune marker increases, suggesting potential efficacy. The data was presented at the AACR Annual Meeting 2022.

AIM ImmunoTech Inc. (AIM) announced positive results from its Phase 2a clinical study on Ampligen for treating colorectal cancer metastatic to the liver. The primary endpoint was achieved with a significant increase in CD8a expression post-treatment (p=0.046), suggesting that the CKM regimen may enhance immunotherapy effectiveness. Data presented at the AACR 2022 showed improved ratios of CD8a/CD4 and CD8a/FOXP3, indicating a favorable immune response. The median overall survival was 10.5 months. However, no tumor responses were observed, and adverse events were reported in 74% of participants.

AIM ImmunoTech reported its 2021 financial results, noting significant progress in its oncology pipeline and Ampligen^® data demonstrating efficacy across various cancer treatments. The FDA lifted the clinical hold on Ampligen's Phase 2 study for pancreatic cancer, allowing advanced trials to proceed. AIM has a strong cash position of $48.3 million as of December 31, 2021, and expects to maintain operations and clinical programs through 2023. The company aims to leverage upcoming clinical and regulatory milestones in 2022 to drive further growth.